Nicholas Nicolaides Keeps Returning to the Same Tiny Question: What Is the Antibody Missing?

He turned a lesson in genetic error correction into one biotech company, stayed after its $325 million sale, then began again with old collaborators and a new puzzle: why good antibodies sometimes go quiet.